整理 | GLP1减重宝典内容团队 一种每日一次口服的减重药物，正被视为注射类GLP-1减肥药之外的更易获得选择。美国生物科技公司Syntis Bio近日宣布，已完成 3800万美元融资，用于加速其口服减重药的研发进程。该药物通过模拟胃旁路手术的生理效果，在不进行侵入性手术的情况下，帮助调 节食欲与代谢。 Syntis Bio总部位于波士顿，本轮融资中，公司完成了3300万美元A轮融资，资金将用于推进核心产品Synt-101的开发，同时还获得了 最高500万美元的非稀释性科研资助。 Synt-101是一款每日服用一次的口服制剂，其作用机制并非直接抑制食欲，而是暂时阻断小肠上段对营养的吸收，并将营养物质重新引 导至下段，从而激活人体自身释放调节饱腹感和代谢的激素反应。该产品基于公司自主研发的"Synt"合成组织内衬技术，通过类似贻贝 黏附机制的涂层，在小肠内形成可持续约24小时的功能性覆盖层。 尽管当前研发重点集中在减重领域，Syntis Bio认为，这一技术平台具备高度延展性，未来可应用于多种疾病治疗场景。 公司披露的临床前数据显示，在动物模型中，Synt-101实现了每周约1%的稳定体重下降，同时瘦体重保持 ...

Core Insights - The market may have prematurely dismissed Viking Therapeutics' pipeline prospects following the phase 2 trial results of VK2735, an oral anti-obesity drug [2][3] - The phase 2 trial showed impressive efficacy but disappointing safety and tolerability data, particularly a 20% discontinuation rate due to adverse events [5][6] - There may still be opportunities for Viking Therapeutics, including potential acquisition or partnership with larger pharmaceutical companies to advance VK2735 through phase 3 testing [8] Company Performance - Viking Therapeutics' phase 2 Venture trial had a 20% discontinuation rate due to adverse effects, compared to 6% for Novo Nordisk's semaglutide and 10.3% for Eli Lilly's orforglipron in their respective phase 3 trials [7] - The body weight reduction in the Venture trial was 12.2%, which is lower than the reductions seen in the phase 3 trials of competitors [7] Market Sentiment - The initial market reaction to the trial results indicated a lack of near-term catalysts for Viking Therapeutics, with phase 3 results for VK2735 in subcutaneous form not expected until 2027 [2] - Despite the negative sentiment, there is a belief that the market may be underestimating Viking's potential options moving forward [3][8]